Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BI 655066 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| i.v. BI 655066 | EXPERIMENTAL | A subject to receive a single i.v. dose of BI 655066 |
| i.v. placebo | PLACEBO_COMPARATOR | A subject to receive a single i.v. dose of placebo |
| s.c. BI 655066 | EXPERIMENTAL | A subject to receive a single s.c. dose of BI 655066 |
| s.c. placebo | PLACEBO_COMPARATOR | A subject to receive a single s.c. dose of placebo |
| Name | Type | Description |
|---|---|---|
| BI 655066 (very high i.v. dose) | DRUG | Single very high i.v. dose BI 655066 |
| Placebo, i.v. | DRUG | Single i.v. administration of placebo |
| BI 655066 (high s.c. dose) | DRUG | Single high s.c. dose BI 655066 |
| BI 655066 (low i.v. dose) | DRUG | Single low i.v. dose BI 655066 |
| BI 655066 (high medium i.v. dose) | DRUG | Single high medium i.v. dose BI 655066 |
| BI 655066 (very low i.v. dose) | DRUG | Single very low i.v. dose BI 655066 |
| BI 655066 (low s.c. dose) | DRUG | Single low s.c. dose BI 655066 |
| BI 655066 (high i.v. dose) | DRUG | Single high i.v. dose BI 655066 |
| Placebo, s.c. | DRUG | Single s.c. administration of placebo |
| BI 655066 (low medium i.v. dose) | DRUG | Single low medium i.v. dose BI 655066 |
Inclusion criteria: 1. Male or female patients aged 18-75 years (inclusive) 2. Chronic moderate to severe plaque psoriasis lasting =\>6 months with involvement of Body Surface Area (BSA) =\>10%, Psoriasis Area and Severity Index (PASI) =\>12 and Static Physician Global Assessment (sPGA) score of mo...
BI 655066 is an investigational small molecule being developed for the treatment of moderate to severe psoriasis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. A single rising dose study has been completed in patients with this condition.
BI 655066 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 1 clinical development for psoriasis.
BI 655066 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial has been completed, and the drug remains under investigation for the treatment of moderate to severe psoriasis.
BI 655066 has one completed Phase 1 clinical trial, identified as NCT01577550, titled "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis." The trial enrolled 39 participants and was conducted in the United States, Germany, and the United Kingdom.
BI 655066 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for psoriasis. The drug has completed a Phase 1 trial, but it has not received regulatory approval and remains under clinical investigation.